TickerTalks
Browse all tickers →
TickerTalks›$KALA
KAKALA

KALA BIO, Inc.

$KALA·$79M·Biotechnology·Healthcare
$3.61+26.9%YTD-87.1%1Y-98.3%
Mentions · last 7 days
0
Price updated 19m ago
KAKALA
KALA BIO, Inc.$KALA
$3.61+26.89%0 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $KALA.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition is the dominant structural driver — the 'next phase' of obesity drugs (oral formulations, differentiated mechanisms) is reshaping clinical bets for NVO competitors. Gene editing (CRSP, BEAM, NTLA, PRME) is transitioning from clinical to commercial-maturation phase with Casgevy scaling; oncology binary events (IBRX, ALLO, KURA) define the near-term calendar.

Top industry ETF

$IBBiShares Biotechnology ETF
+2.4%YTD
+38.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-282%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-32.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-13.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 15, 2026$-0.14$-8.50+98.4%
Q1 2026Apr 15, 2026$0.08$-16.00+100.5%
Q3 2025Nov 19, 2025$-1.07$-1.01-5.9%
Q2 2025Aug 8, 2025$-1.71$-1.82+6.0%
Next earningsThu, Aug 6·consensus EPS $-6.00

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.20$-2.9M
Q4 FY25$0———$0.08$-4.6M
Q3 FY25$0———$-1.07$-10.9M
Q2 FY25$0———$-1.71$-7.7M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$25.0M$25.0M – $25.0M-$26.50-$26.50 – -$26.501
FY27$26.1M$26.1M – $26.1M-$20.00-$20.00 – -$20.001
FY28$134.2M$134.2M – $134.2M-$9.00-$9.00 – -$9.001
FY29$229.3M$229.3M – $229.3M-$8.50-$8.50 – -$8.501

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.9.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-24.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-96.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-3/AShelf registrationJun 12S-3/A
AI summary

Kala Bio (KALA) filed Amendment No. 1 to its Form S-3 shelf registration (Registration No. 333-295667) on June 12, 2026 as a smaller reporting company. This is a routine amendment to an existing shelf filing, typically filed to update financial statements or other disclosure; no new offering terms were specified in the excerpt.

S-3Shelf registrationMay 7S-3
AI summary

Kala Bio (KALA) filed an initial Form S-3 shelf registration statement on May 7, 2026 as a smaller reporting company. The specific aggregate offering amount was not disclosed in the excerpt. This is a routine shelf filing enabling future capital raises.

8-KCharter amendmentMay 78-K — Item 3.03 · Item 5.03: Charter amendment · Item 8.01: Other event
AI summary

Kala Bio (KALA) effected a 1-for-50 reverse stock split, effective May 8, 2026 at 4:05 PM Delaware time. The Certificate of Amendment to the Certificate of Incorporation was filed on May 7, 2026 (Item 5.03). The split also triggered Item 3.03 (material modification to rights of holders) and Item 8.01. Reverse splits at this ratio typically reflect a stock trading at very low prices, potentially to regain or maintain exchange listing compliance.

8-KMaterial agreementMar 48-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
8-KOfficer or director changeFeb 208-K — Item 5.02: Officer or director change
S-3Shelf registrationFeb 10S-3
3New insider — initial holdingsFeb 93
3New insider — initial holdingsFeb 93
+ 26 other (6 8-Ks · 3 13Gs · 3 3s · 3 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

KALA BIO Announces Reverse Stock Splitglobenewswire.com·44d agoKala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicineglobenewswire.com·60d agoKALA BIO (NASDAQ:KALA) vs. Celularity (NASDAQ:CELU) Financial Surveydefenseworld.net·75d agoKala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunitiesglobenewswire.com·80d agoKALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Liveglobenewswire.com·82d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$ALT$IBRX$QURE$RXRX
Voices on X · last 7 days

No standout posts about $KALA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport